Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
hDPP9 Inhibition Assay from US Patent US20230406840: "N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES"
Assay data:2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
hDPP9 Inhibition Assay from US Patent US20230312550: "N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES"
Assay data:15 Active, 6 Activity ≤ 1 µM, 15 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
hDPP8 Inhibition Assay from US Patent US20230312550: "N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES"
Assay data:14 Active, 2 Activity ≤ 1 µM, 15 Tested
In Vitro Inhibition Assay from US Patent US11583516: "Dash inhibitors, and uses related thereto"
Assay data:13 Active, 1 Activity ≤ 1 nM, 13 Activity ≤ 1 µM, 13 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
EnPlex (purified enzyme activity assay) from US Patent US11559537: "Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists"
Assay data:49 Active, 10 Activity ≤ 1 nM, 47 Activity ≤ 1 µM, 50 Tested
DPP9 Enzymatic Activity Assay from US Patent US11504364: "Inhibitors of fibroblast activation protein"
Assay data:11 Active, 4 Activity ≤ 1 µM, 62 Tested
In Vitro Inhibition Assay from US Patent US11096924: "Combination therapies using immuno-dash inhibitors and PGE2 antagonists"
Assay data:34 Active, 10 Activity ≤ 1 µM, 49 Tested
Enzymatic Assay from US Patent US9346814: "FAP inhibitors"
Assay data:45 Active, 32 Activity ≤ 1 µM, 49 Tested
Kinetics Assays from Article 10.1074/jbc.M113.489179: "The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9."
Assay data:6 Active, 4 Activity ≤ 1 µM, 7 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
DPP-IV Inhibition Screening Assay from Article 10.1111/cbdd.12663: "Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors."
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
DPP-IX Assay from US Patent US8470836: "Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent"
Assay data:6 Tested
SummaryRelated BioAssays by DepositorRelated BioAssays by Target
DPP-VIII Assay from US Patent US8470836: "Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent"
Dipeptidyl Peptidase Inhibition Assay from Article 10.1016/j.bmcl.2007.02.066: "4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV."
Assay data:26 Active, 26 Activity ≤ 1 µM, 26 Tested
DPP Inhibition Assay from Article 10.1021/jm070104l: "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV."
Assay data:14 Active, 14 Activity ≤ 1 µM, 14 Tested
Dipeptidyl Peptidase Inhibition Assay from Article 10.1016/j.bmcl.2007.01.039: "Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes."
Assay data:30 Active, 30 Activity ≤ 1 µM, 30 Tested
DPP Inhibition Assay from Article 10.1021/jm061436d: "Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors."
Assay data:24 Active, 22 Activity ≤ 1 µM, 24 Tested
DPP Inhibition Assay from Article 10.1016/j.bmcl.2007.01.026: "Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit."
Assay data:27 Active, 24 Activity ≤ 1 µM, 28 Tested
DPP Inhibition Assay from Article 10.1016/j.bmcl.2006.09.024: "Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors."
Assay data:15 Active, 14 Activity ≤ 1 µM, 15 Tested
Dipeptidyl Peptidase Inhibition Assay from Article 10.1016/j.bmcl.2006.09.099: "(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes."
Assay data:15 Active, 3 Activity ≤ 1 nM, 14 Activity ≤ 1 µM, 16 Tested
DPP Inhibition Assay from Article 10.1021/jm060955d: "Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes."
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on